Intermediate dose heparin thromboprophylaxis among critically ill patients with COVID-19: a randomized clinical trial.
Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP-CAP) Investigators; Bradbury CA, McVerry BJ, Lawler PR, Angus DC, Annane D, Arabi YM, Aryal D, Au C, Beane A, Berry SM, Berry LR, Best-Lane J, Bihari S, Bonten M, Brunkhorst F, Burrell A, Buxton M, Carrier M, Cecconi M, Cheng AC, Cove M, Derde LPG, Detry MA, Estcourt LJ, Fergusson DA, Fitzgerald M, Fowler RA, Goligher EC, Green C, Haniffa R, Harrison DA, Hays LMC, Higgins AM, Hills T, Horvat CM, Huang DT, Hunt BJ, Ichihara N, Jayakumar D, Keattch S, Kumar A, Laffan MA, Lamontagne F, Leeper CM, Lewis RJ, Lorenzi E, Lother SA, Marshall JC, McArthur CJ, McAuley DF, McGlothlin A, McGuinness SP, McQuilten ZK, Middeldorp S, Morpeth S, Mouncey PR, Murthy S, Neal MD, Nichol AD, Parke RL, Parker JC, Peters S, Reyes LF, Rowan K, Saito H, Santos M, Saunders CT, Schutgens REG, Seymour CW, Hari MS, Singh V, Stanworth SJ, Turgeon AF, Turner AM, van de Veerdonk FL, Gordon AC, Webb SA, Zarychanski R.
Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP-CAP) Investigators, et al. Among authors: marshall jc.
J Thromb Haemost. 2026 Mar 25:S1538-7836(26)00191-1. doi: 10.1016/j.jtha.2026.03.006. Online ahead of print.
J Thromb Haemost. 2026.
PMID: 41895526
Free article.